COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND INFLIXIMAB IN PSORIATIC ARTHRITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE 3 CLINICAL TRIAL DATA

被引：1
|
作者：
Strand, V. [1 ]
McInnes, I. [2 ]
Mease, P. [3 ,4 ]
Choy, E. [5 ]
Nash, P. [6 ]
Thom, H. [7 ]
Kalyvas, C. [8 ]
Gandhi, K. [9 ]
Pricop, L. [9 ]
Jugl, S. [10 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Cardiff Univ, Cardiff, S Glam, Wales
[6] Univ Queensland, Brisbane, Qld, Australia
[7] Univ Bristol, Bristol, Avon, England
[8] MAPI Grp, Houten, Netherlands
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5802
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0480
引用
收藏
页码：957 / 957
页数：1
相关论文
共 50 条
  • [31] SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Maksymowych, W.
    Strand, V
    Baeten, D.
    Nash, P.
    Thom, H.
    Hunger, M.
    Gandhi, K.
    Richards, H.
    Jugl, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 782 - 782
  • [32] SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Maksymowych, W.
    Strand, V.
    Baeten, D.
    Nash, P.
    Thom, H.
    Cure, S.
    Palaka, E.
    Gandhi, K.
    Richards, H.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 98 - 98
  • [33] MATCHING-ADJUSTED INDIRECT COMPARISON OF IXEKIZUMAB VS. TOFACITINIB IN PSORIATIC ARTHRITIS
    Sapin, C.
    Panni, T.
    Meszaros, G.
    Hill, J.
    Hartz, S.
    VALUE IN HEALTH, 2020, 23 : S593 - S593
  • [34] COMPARATIVE EFFECTIVENESS OF PEGCETACOPLAN VERSUS RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MATCHING-ADJUSTED INDIRECT COMPARISON USING 26 WEEK PEGASUS PHASE 3 TRIAL DATA
    Bhak, Rachel
    Mody-Patel, Nikita
    Baver, Scott
    Kunzweiler, Colin
    Yee, Christopher
    Sundaresan, Sanjana
    Swartz, Natalia
    Duh, Mei Sheng
    Krishnan, Sangeeta
    Sarda, Sujata
    EXPERIMENTAL HEMATOLOGY, 2021, 100 : S65 - S65
  • [35] Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
    Mahon, Ronan
    Tiwari, Santosh
    Koch, Mirja
    Ferraris, Matias
    Betts, Keith A.
    Wang, Yan
    Gao, Sophie
    Proot, Pascal
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (03)
  • [36] Comparative effectiveness of ozanimod versus dimethyl fumarate: results of a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [37] Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective
    Greenberg, Jeffrey D.
    Nikoglou, Efthalia
    Gunda, Praveen
    Palmer, Jacqueline
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [38] A COST PER RESPONDER ANALYSIS OF SECUKINUMAB VS. ADALIMUMAB BASED ON A MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY DATA FOR THE TREATMETN OF PSORIATIC ARTHRITIS AT 48 WEEKS FROM THE IRISH PAYER PERSPECTIVE
    Gunda, P.
    Nikoglou, E.
    Jugl, S. M.
    Murphy, A.
    VALUE IN HEALTH, 2017, 20 (09) : A532 - A532
  • [39] Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis
    Fox, Robert J.
    Chan, Andrew
    Zhang, Annie
    Xiao, James
    Levison, Dane
    Lewin, James B.
    Edwards, Michael R.
    Marantz, Jing L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (02) : 175 - 183
  • [40] Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
    Huizinga, Thomas
    Choy, Ernest
    Praestgaard, Amy
    van Hoogstraten, Hubert
    LaFontaine, Patrick R.
    Guyot, Patricia
    Aletaha, Daniel
    Mueller-Ladner, Ulf
    Tanaka, Yoshiya
    Curtis, Jeffrey R.
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345